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In the bone marrow, endothelial cells are a major component of thehematopoietic stem cell vascular niche and are a first line of defenseagainst inflammatory stress and infection. The primary response of an
organism to infection involves the synthesis of immune-modulatory
cytokines, including interferon alpha. In the bone marrow, interferon
alpha induces rapid cell cycle entry of hematopoietic stem cells in vivo.
However, the effect of interferon alpha on bone marrow endothelial cells
has not been described. Here, we demonstrate that acute interferon
alpha treatment leads to rapid stimulation of bone marrow endothelial
cells in vivo, resulting in increased bone marrow vascularity and vascular
leakage. We find that activation of bone marrow endothelial cells
involves the expression of key inflammatory and endothelial cell-stimu-
latory markers. This interferon alpha-mediated activation of bone mar-
row endothelial cells is dependent in part on vascular endothelial growth
factor signaling in bone marrow hematopoietic cell types, including
hematopoietic stem cells. Thus, this implies a role for hematopoietic
stem cells in remodeling of the bone marrow niche in vivo following
inflammatory stress. These data increase our current understanding of
the relationship between hematopoietic stem cells and the bone marrow
niche under inflammatory stress and also clarify the response of bone
marrow niche endothelial cells to acute interferon alpha treatment in vivo.
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ABSTRACT
Introduction
Tissue vasculature serves as a barrier between sites of inflammation or infection
and immune cells.1 Endothelial cells (ECs) are a diverse cell population which line
the vasculature. These cells form a cell monolayer and are interconnected by junc-
tion molecules, including VE-cadherin and ESAM. This regulatory monolayer is
ensheathed by pericytes and forms a selective, semi-permeable barrier that regu-
lates tissue fluid homeostasis and migration of blood cells through the vessel wall.2
Thus, ECs are primary responders to inflammation and infection. During an inflam-
matory response, ECs proliferate in order to maintain vessel integrity.3 Immune cell
loss, as well as interactions between immune cells and ECs, facilitates the emigra-
tion of circulating cells across the EC barrier to sites of inflammation. This process
can, in turn, lead to EC activation.4,5 Production of pro-inflammatory factors and
the interaction between stimulatory cytokines and chemokines is a critical step in
the inflammatory response. Interferon α (IFNα) is one of the most prominent
immune-modulatory cytokines which is produced to facilitate the response to
inflammation. Vascular endothelial growth factor (VEGF) regulates ECs during both
homeostasis and inflammation. VEGF regulation is central to vascular dynamics,
promoting EC survival, proliferation and migration.4,6  
In the bone marrow (BM) microenvironment, the vascular system consists of a
network of sinusoids, arterioles, and transition zones. Subtypes of BM vessels are
heterogenous in both properties and functions.7,8 BM ECs
form a critical part of the hematopoietic stem cell (HSC)
vascular niche. ECs have well-defined roles in HSC func-
tion and maintenance, retaining HSCs in culture and con-
tributing to the creation of HSC niches.9-13 In vivo ablation
of ECs leads to hematopoietic failure.14 In response to
infection, hematopoietic cells mediate an altered expres-
sion of adherens molecules on the surface of ECs.13,15 This
suggests that HSCs may also directly affect ECs. However,
in contrast to the defined roles for ECs on HSCs, the effect
of HSCs on ECs in the BM niche remains unclear. In addi-
tion, little is known about the influence of inflammatory
stress on ECs in the BM, or the interaction between IFNα
and VEGF.
The stimulatory effect of IFNα on HSCs in vivo is not
reflected in vitro. In vitro, IFNα has an inhibitory effect
which leads to inhibition of HSC proliferation.16 This sug-
gests a role for the BM niche, including ECs, in inflamma-
tion-induced HSC stimulation. However, how crosstalk
between HSCs and ECs in the BM is regulated under
inflammatory stress remains unknown. To understand
how inflammatory stress impacts on ECs in the BM niche,
we  investigated how BM ECs respond to IFNα in vivo and
how the interaction between HSCs and ECs is regulated.
We found that IFNα treatment of mice led to a rapid stim-
ulation of BM ECs in vivo. IFNα stimulation of ECs was
both direct and indirect. VEGF signaling, mediated by
other BM hematopoietic cell types including HSCs, was a
central mediator of the observed EC stimulation. This
novel communication between activated hematopoietic
cells and ECs in the BM suggests an acute 'emergency'
response of the BM niche to primary inflammatory signal-
ing  from the hematopoietic system.
Methods 
Animals
Eight- to 12-week old female wild-type (WT) mice [C57Bl/6J
(CD45.2), Harlan Laboratories or B6.SJL-Ptprca Pepcb/BoyJ
(CD45.1), Charles River Laboratories] and IFNAR–/– mice17 were
maintained in individually ventilated cages in the Deutsches
Krebsforschungszentrum  animal facility. All animal protocols
were approved by the Animal Care and Use Committees of the
German Regierungspräsidium Karlsruhe für Tierschutz und
Arzneimittelüberwachung. 
In vivo treatments
Mice were injected intraperitoneally (i.p.) with PBS, 5 mg/kg
polyinosinic-polycytidylic acid (pI:C) (Invitrogen), subcutaneously
(s.c) with 5x106U/kg recombinant mouse IFNα (Miltenyi Biotech)
or intravenously (i.v.) with 2.5 mg/kg Avastin (Roche).
In vivo vascular labeling
In vivo labeling was carried out as described by Kunisaki et al.18
Evans blue assay
Evans blue assay was carried out as described by Radu et al.19
Isolation of BM Cells and flow cytometry
Mice were sacrificed and BM cells were subsequently prepared
and analyzed as described in Haas et al.20 In addition, ECs were
stained using antibodies against CD4, CD8 CD11b, B220a, Gr-1
and TER119 as indicated,20 and CD45 (30-F11), CD31 (390), VE-
Cadherin (VECD1), VEGFR2 (Avas12), ESAM (1G8) (Biolegend),
and Laminin (Sigma). Cells were stained with anti-VEGF antibody
according to the manufacturer's instructions (Abcam).  
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Figure 1. Interferon α (IFNα) treatment leads to increased bone marrow (BM) vascularity and vascular permeability. (A) Representative sections of murine femurs,
with metaphysis and diaphysis regions indicated, from wild-type (WT) C57Bl/6 mice treated with either PBS or the IFN mimetic, pI:C, (5 mg/kg for 24 h). 8 μm sec-
tions of femurs were stained with Laminin (green) and mounted in DAPI containing mountant (blue). Scale bar represents 100 mm. (B)  Quantification of Laminin
positive vasculature in BM sections. Corrected total cell fluorescence is represented as Arbitrary Units (AU). (C) Laminin expression on ECs (Lin– CD45– CD31+) from
WT mice treated with either PBS, pI:C (5 mg/kg for 24 h) or IFNα (5x106U/kg for 24 h) was quantified by flow cytometry. (D) Graph representing the vessel diameter
in BM from WT mice treated with either PBS or pI:C (5 mg/kg for 24 h) quantified following in vivo labeling with Alexa 633. (E) Evans blue assay to determine vessel
leakiness in WT and IFNAR–/– mice treated with PBS (0 h) or pI:C (5 mg/kg for 24 h). Absorbance was measured at 620 nm. Data are representative of 3 or more
independent experiments. Data are presented as mean±Standard Error of Mean (SEM) (n≥3). Statistical analysis was performed using unpaired Student t-test (two-








Vascular endothelial growth factor ELISA 
ELISA was carried out on BM supernatant from one crushed
tibia and femur per mouse according to the manufacturer's
instructions (BD Bioscience). 
BrdU incorporation assay
Mice were injected i.p. with BrdU (18 mg/kg, Sigma) 16 h prior
to harvesting the BM. BM cells were stained as described and
BrdU staining was carried out using the BD PharmigenTM BrdU
Flow Kit according to the manufacturer’s instructions.
Bone marrow transplantations
3x106 BM cells were diluted in 200 ml PBS and i.v. injected into
lethally irradiated (2x500 rad) WT or IFNAR–/– mice. 
Immunofluorescence of bone sections
8 mm bone sections of frozen femurs were prepared using the
Kawamoto tape method.21 In brief, sections were stained
overnight using anti-VEGFR2 (Avas12) and anti-Laminin antibod-
ies, and subsequently with Alexa Fluor 488 secondary antibody
(Jackson) for 1 h at room temperature. Images were acquired using
an LSM710 microscope and were prepared using FIJI software.
Corrected total cell fluorescence was calculated as: integrated den-
sity - (area of selected cell x mean fluorescence of background
readings). 
Statistical analysis
GraphPad Prism® 6.0 was used for statistical analysis and
graphical representation of data. Statistical analysis was per-
IFNα mediated remodeling of BM endothelial cells 
haematologica | 2017; 102(3) 447
Figure 2. Bone marrow (BM) endothelial cells (EC) are stimulated following interferon α (IFNα) treatment in vivo. (A) FACS analysis of percentage of BrdU positive
ECs (Lin– CD45– CD31+) from wild-type (WT) or IFNAR–/– mice treated with either phosphate-buffered saline (PBS) (0 h) or IFNα (5x106U/kg for up to 24 h) and BrdU
(18 mg/kg, 16 h). (B) Percentage of Lin- CD45- CD31+ BM cells in BM from WT mice treated with either PBS, the interferon mimetic, pI:C, (5 mg/kg for 24 h), or IFNα
(5x106U/kg for 24 h). (C and D) FACS analysis of the expression of ESAM, VE-Cadherin or Laminin on ECs (Lin- CD45- CD31+) from (C) WT mice treated with either
PBS or IFNα (5x106U/kg for 24 h) or (D) IFNAR–/– mice treated with either PBS or pI:C (5 mg/kg for 24 h). (E and F)  FACS analysis of the expression of ESAM, VE-
Cadherin or Laminin on ECs (Lin– CD45– CD31+) from WT mice treated with either (E) pI:C (0-5 mg/kg for 24 h) or (F) IFNα (0-5x106U/kg for 24 h). (G) FACS analysis
of the expression of Laminin on ECs (Lin– CD45– CD31+) from WT mice treated with either PBS (0 h) or pI:C (5 mg/kg for 0-120 h). (H) FACS analysis of the expression
of VE-Cadherin and ESAM on ECs (Lin– CD45– CD31+) from WT mice treated with either PBS (0 h) or pI:C (5 mg/kg for 0-120 h). Data are representative of 3 or more
(A-C) or 2 or more (D-H) independent experiments. Data are presented as mean±Standard Error of Mean (SEM) (n≥3). Statistical analysis was performed using
unpaired Student t-test (two-tailed). ns: not significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
Figure 3. Bone marrow (BM) endothelial cells (EC) are not activated by multiple rounds of treatment with the interferon mimetic, pI:C. (A) Experimental design. 1x:
treatment with  PBS or interferon, pI:C, for 24 h. 8x: treatment with PBS or pI:C every second day for 16 days. Mice were sacrificed 24 h after final treatment (on day
17). (B) FACS analysis of the expression of ESAM, VE-Cadherin and Laminin on ECs (Lin– CD45– CD31+) from wild-type (WT) mice treated with either 1 round or 8
rounds of PBS or pI:C (5 mg/kg). (C) Data are representative of  2 or more independent experiments and data are presented as mean±Standard Error of Mean (SEM)
(n≥3). Statistical analysis was performed using unpaired Student t-test (two-tailed). ns (not significant), *P<0.01, **P<0.0001
A B C D
E F G H
A B
formed using unpaired Student t-test (two-tailed). All data are
expressed as mean±Standard Error of Mean (SEM) unless other-
wise indicated. Statistical significance is indicated in the individual
figures.  
Results
Acute inflammatory stress induces increased BM 
vascularity and vessel permeability
To monitor the response of the BM vasculature to
inflammatory stress, we treated  WT C57Bl/6 mice with a
single dose of the IFNα mimetic, pI:C, to mimic an acute
inflammatory response. After 24 h, there was a significant
increase in BM vasculature in both the diaphysis and
metaphysis regions of the BM in pI:C-treated WT mice in
comparison to mice treated with PBS, as visualized and
quantified by anti-Laminin staining in frozen BM sections
(Figure 1A and B). Increased expression of Laminin on ECs
upon injection of either pI:C or IFNα was confirmed by
FACS analysis (Figure 1C). To quantify the IFNα-mediated
increase in vasculature, BM vessels were directly labeled in
vivo by i.v. injection of Alexa Fluor 633 phalloidin18 (Figure
1D). Quantification of BM vessel diameter based on Alexa
633 labeling showed that the BM vasculature became
enlarged 24 h following pI:C treatment. The integrity of
the BM vasculature was quantified using an Evans blue
assay, as previously described.19 Evans blue staining in the
BM of PBS-treated mice showed basal efflux of macromol-
ecules over the EC vasculature under homeostasis (0 h,
Figure 1E). However, 24 h after pI:C treatment, BM Evans
blue staining increased 2-fold in WT mice, but not in mice
lacking the IFNα receptor (IFNAR–/–) (Figure 1E). This indi-
cated that increased vessel leakage was the result of IFNα
signaling. Taken together, the observed increase in BM
vascularity, Laminin expression on ECs and compromised
vessel integrity suggests that acute inflammatory signaling
stimulates the vasculature within the BM.
Acute inflammatory stress induces transient BM EC
proliferation and activation in vivo
To investigate whether the observed vascular expansion
was due to an increased activation of ECs, we next ana-
lyzed the proliferative and activation status of ECs follow-
ing IFNα treatment. BrdU incorporation was increased
after 4 h in BM ECs (Lin– CD45– CD31+) from mice treated
with IFNα in comparison to PBS-treated mice (Figure 2A
and B). This suggested an increase in cells which were in
S-phase of the cell cycle. IFNα treatment of IFNAR–/– mice
confirmed that the increased BrdU incorporation was due
to IFN signaling. To determine the activation status of BM
ECs, we analyzed the expression of the key cellular junc-
tion proteins ESAM, VE-cadherin and Laminin.22 Twenty-
four hours after either IFNα or pI:C treatment of mice,
expression of ESAM, VE-cadherin and Laminin were up-
regulated on the surface of WT BM ECs (Figure 2C) but
not on IFNAR–/– BM ECs (Figure 2D). Indeed, increased BM
EC activation was detectable even from low-dose treat-
ment. Exposure of mice to low-dose pI:C (0.5 mg/kg)
(Figure 2E) or IFNα (0.1 Units/kg) (Figure 2F) led to
increased expression of activation markers. These data
indicated that BM ECs were activated by IFNα or pI:C
treatment in an IFNα-dependent manner, and that BM ECs
were activated even in response to low doses of treat-
ment. When mice were allowed to recover after treat-
ment, upregulation of Laminin (Figure 2G), VE-Cadherin
Á.M. Prendergast et al.
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Figure 4. Bone marrow (BM) endothelial cell (EC) activation can be mediated by the interferon (IFN) mimetic, pI:C, stimulation of hematopoietic or non-hematopoi-
etic cells. (A) Experimental design: 3x106 BM cells from either wild-type (WT) (CD45.1) or IFNAR-/- (CD45.2) mice was transplanted into lethally irradiated IIFNAR-/- or
WT mice, respectively. Mice were allowed to recover for 90 days (d) prior to treatment with either PBS or pI:C (5 mg/kg for 24 h). (B) FACS analysis of percentage of
BrdU positive HSCs (Lin- ckithi CD150+CD48-) from chimeric mice, as described in (A) following treatment with either PBS or pI:C (5 mg/kg for 24 h) and BrdU (18
mg/kg, 16 h). (C-E) FACS analysis of the expression of (C) Laminin (D) VE-Cadherin and  (E) ESAM on ECs (Lin- CD45- CD31+) from chimeric mice, as described in
(A) following treatment with either PBS or pI:C (5 mg/kg for 24 h). Data are representative of  3 or more  (B) and 2 or more  (C-E) independent experiments, and data




and ESAM (Figure 2H)  returned to homeostatic levels
after 96 h. This indicated that, similar to the response of
HSCs,16 the rapid response of ECs to IFNα treatment is
transient. Thus, EC proliferation and activation is modu-
lated following acute IFNα treatment. Proliferation and
activation are dependent on expression on the IFNα recep-
tor. Taken together with increased vascularity and com-
promised BM vessel integrity (Figure 1), EC proliferation
and activation indicate enhanced BM vessel remodeling
occurs.
To test whether chronic IFNα treatment could lead to an
accumulation or an exhaustion of BM EC activation, as
previously described,23 mice were treated with pI:C every
second day for a total of 16 days (Figure 3A). In contrast to
the increase in activation markers upon 1 injection (1x),
BM ECs expressed homeostatic levels of ESAM, VE-
Cadherin and Laminin after multiple injections with pI:C
(8x) (Figure 3B). Thus, BM ECs were not continually acti-
vated by multiple treatments of pI:C. These data are
indicative of the contrast in the response of BM ECs, as
well as HSCs, to acute and chronic IFNα treatment.23 This
supports the hypothesis of a rapid, acute stimulation of
BM ECs following inflammation. 
BM EC stimulation by IFNα occurs via both 
hematopoietic and non-hematopoietic pathways
IFNα has been reported to have heterogenous effects on
ECs.24-28 We tested whether the observed stimulatory
effect of IFNα on BM ECs was directly or indirectly medi-
ated by IFNα.16 BM chimeras were created where either
WT or IFNAR–/– BM cells were transplanted into lethally
irradiated IFNAR–/– or WT host mice, respectively. Thus,
either the BM (IFNAR–/– BM into a WT niche) or the niche
(WT BM into an IFNAR–/– niche) can no longer directly
respond directly to IFNα in these mice (Figure 4A). In
agreement with our previous data,16 WT HSCs in recipient
IFNAR–/– mice (WT BM into an IFNAR–/– niche) proliferated
in response to pI:C treatment; IFNAR–/– HSCs in WT recip-
ient mice (IFNAR–/– BM into a WT niche) did not (Figure
4B). This indicated that the response of HSCs to pI:C was
dependent on the expression of the IFNα receptor (IFNAR)
on HSCs, not on niche cells. In contrast, Laminin (Figure
4C), VE-Cadherin (Figure 4D) and ESAM (Figure 4F)
expression was increased on IFNAR–/– ECs with a WT
hematopoietic system present (WT BM into an IFNAR–/–
niche) and on WT ECs with a hematopoietic system  lack-
ing the IFNα receptor (IFNAR–/– BM into a WT niche).
These data indicated that BM ECs can be stimulated by
IFNα via a non-hematopoietic effect of IFNα directly on
the BM ECs as well as an indirect effect of IFNα via signal-
ing from IFNα-stimulated hematopoietic cells in the BM. 
pI:C treatment induces VEGF production and signaling
in the BM
Bone marrow chimera experiments suggested that
IFNα-stimulated hematopoietic cells may produce factors
which can stimulate BM ECs (Figure 4C and E). Thus, we
next tested the activity of known mediators of EC activa-
tion in this setting. Platelet activation and VEGF signaling
are fundamental mediators of EC activation during inflam-
IFNα mediated remodeling of BM endothelial cells 
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Figure 5. The IFN mimetic-, pI:C, mediated bone marrow (BM) endothelial cell (EC) stimulation is not affected by platelet abrogation. (A) Experimental design: mice
were treated with the anti-platelet antibody R300 (2 mg/g) and either PBS or the IFN mimetic, pI:C, (5 mg/kg) for 24 h. (B) Platelet counts in the peripheral blood of
wild-type (WT) mice following treatment as outlined in (A). (C-E) FACS analysis of the expression of (C) ESAM (D) VE-Cadherin and (E) Laminin on ECs (Lin- CD45-
CD31+) from WT mice treated as outlined in (A). Data are representative of 3 or more independent experiments, and are presented as mean±Standard Error of Mean




mation,29,30 and megakaryocytes, which give rise to
platelets, regulate BM HSC quiescence.31 To test pI:C-
mediated EC activation in the absence of platelets, mice
were treated with a platelet depletion antibody, anti-
GPIbα (CD42b) antibody (R300), prior to pI:C administra-
tion (Figure 5A). Platelet levels were reduced upon R300
treatment (Figure 5B); however, EC activation markers
were not altered following platelet depletion (Figure 5C-
E). This suggested that platelet activation was not central
to IFNα-induced BM EC stimulation. To investigate
whether VEGF was regulated by acute pI:C treatment, we
carried out a BM ELISA and intracellular staining for VEGF
in BM cell types following pI:C treatment. After 24 h there
was a significant increase in secreted VEGF in the BM
supernatant of pI:C treated mice (Figure 6A). Intracellular
VEGF did not increase in BM ECs (Figure 6B and C).
However, there was a significant increase in intracellular
VEGF in hematopoietic cells, including progenitors and
HSCs (Lin– ckithi CD150+ CD48– CD34–), both after pI:C
(Figure 6B) and IFNα (Figure 6C) treatment. Consistent
with the transient increase in activation of BM ECs (Figure
2G and H), the increase in intracellular VEGF levels in
HSCs upon pI:C treatment was also transient. VEGF pro-
duction peaked after 24 h and returned to homeostatic lev-
els 72 h after treatment (Figure 6D). In addition, VEGF pro-
duction was increased in WT HSCs in recipient IFNAR–/–
mice (WT BM into an IFNAR–/– niche) and in IFNAR–/–
HSCs in WT recipient mice (IFNAR–/– BM into a WT niche)
following pI:C treatment (Figure 6E). These data suggested
that production of VEGF production in HSCs was stimu-
lated both directly and indirectly by pI:C treatment. To
assess whether VEGF signaling was consequently active in
the BM,6 the expression of the VEGF receptor, VEGFR2,
was analyzed in pI:C treated mice as an indicator of VEGF
signaling. VEGFR2 expression was increased in BM sec-
tions (Figure 6F). In addition, VEGFR2 was up-regulated
on the surface of ECs, but not on HSCs, in response to
both pI:C and IFNα (Figure 6G-I). This suggested that
VEGF signaling was active in ECs but differs between ECs
and HSCs at this time point. As with VEGF production
(Figure 6D), the increase in VEGFR2 expression on BM
ECs was transient, peaking 24 h after pI:C treatment
(Figure 6J). This time point correlated with the peak of
increased expression of activation markers on BM ECs
(Figure 2G and H). Taken together, these data indicate that
pI:C and IFNα treatment leads to an increase in VEGF pro-
duction and signaling in the BM. In addition, they suggest
that, upon pI:C treatment of mice, BM ECs responded to
VEGF, which is produced by other BM cell types including
HSCs in response to pI:C. Thus, VEGF may be a mediating
factor in the activation of BM ECs by 
IFNα-stimulated hematopoietic cells.
IFNα-mediated stimulation of ECs in vivo is facilitated
by VEGF 
To test whether VEGF signaling was involved in BM EC
activation, mice were co-treated with pI:C and the VEGF
binding antibody, Avastin (Figure 7A). Avastin treatment
did not affect the expression of VEGF or VEGFR2 in com-
parison to PBS-treated mice (Figure 7B-D). While the
expression level of VEGF in ECs was unchanged (Figure 7B),
pI:C-induced VEGF expression in HSCs (LK SLAM CD34–)
was significantly reduced by co-treatment with Avastin
(Figure 7C). In addition, the pI:C-induced expression of
VEGFR2 on BM ECs was reduced upon Avastin co-treat-
ment (Figure 7D). In contrast, Avastin treatment did not
affect pI:C-mediated proliferation of HSCs (Figure 7E). This
suggests that co-treatment with Avastin leads to reduced
pI:C-mediated VEGF signaling in the BM. To assess the
effect of diminished VEGF signaling on pI:C-mediated EC
Á.M. Prendergast et al.
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Figure 6. Bone marrow (BM) vascular endothelial growth factor (VEGF) is modulated by the interferon mimetic, pI:C. (A) ELISA of BM VEGF from wild-type (WT) mice
treated with PBS or  the IFN mimetic, pI:C, (5 mg/kg for 24 h). (B and C) FACS analysis of intra-cellular staining of VEGF in indicated BM cell types after treatment
with either PBS, (B) pI:C (5 mg/kg for 24 h), or (C) IFNα (5x106U/kg for 24 h). Data are presented as fold change in mean fluorescence intensity (MFI). (D) FACS analy-
sis of intra-cellular staining of VEGF in hematopoietic stem cells (HSCs) (Lin–ckithi CD150+CD48– CD34–) after treatment with either PBS (0 h) or pI:C (5 mg/kg, 0-120
h). Data are presented as fold change in MFI. (E) FACS analysis of intra-cellular staining of VEGF in HSCs (Lin– ckithi CD150+CD48–CD34–) from chimeric mice, as
described in Figure 4A, following treatment with either PBS or pI:C (5 mg/kg for 24 h). Data are presented as fold change in MFI. (F) Representative bone sections
of VEGFR2 expression (Red) and Laminin (Green) after treatment with either PBS or pI:C (5 mg/kg for 24 h). (G) FACS analysis of VEGFR2 expression on (F)
Lamininhigh/low ECs (Lin– CD45– CD31+, Lamininhigh/low) treated with PBS or pI:C (5 mg/kg for 24 h). (H and I) FACS analysis of VEGFR2 expression on ECs (Lin- CD45-
CD31+) and HSCs (Lin– ckithi CD150+CD48– CD34–) from mice treated with either (H)  PBS or pI:C (mg/kg for 24 h) or (I) PBS or IFNα (5x106U/kg for 24 h). (J) FACS
analysis of the expression of VEGFR2 on ECs from WT mice treated  with either PBS or pI:C (5 mg/kg for up to 120 h). Data are representative of 3 or more inde-
pendent experiments (A, B, D-G) and 2 or more (C and  H) independent experiments, and are presented as mean±Standard Error of Mean (SEM) (n≥3). Statistical
analysis was performed using unpaired Student t-test (two-tailed). ns: not significant, *P<0.05, **P<0.01, ***P<0.001.  
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activation, the expression of EC activation markers follow-
ing Avastin treatment was analyzed. While the increased
expression of ESAM was not affected, the pI:C-induced
expression of both VE-Cadherin and Laminin was signifi-
cantly diminished upon co-treatment with Avastin (Figure
7F and G). This indicated that VEGF was involved, in part,
in pI:C-mediated BM EC activation. Taken together, these
data demonstrate that VEGF signaling is important for the
stimulation of BM ECs following pI:C treatment. 
Discussion 
Bone marrow ECs are a primary defense against infec-
tion, so understanding the effect of inflammation on the
BM vasculature is critical. We demonstrate for the first
time a rapid, transient activation of the BM vasculature in
response to acute inflammatory signaling. We find that
there is a direct and indirect effect of IFNα signaling in the
BM on ECs, mediated by an activated hematopoietic sys-
IFNα mediated remodeling of BM endothelial cells 
haematologica | 2017; 102(3) 451
Figure 7. The IFN mimetic-, pI:C, mediated stimulation of bone marrow (BM) endothelial cells (ECs) is mediated by vascular endothelial growth factor (VEGF) sig-
naling. (A) Experimental design: mice were treated with Avastin (2.5 mg/kg) and either  PBS or the interferon mimetic, pI:C, (5 mg/kg) for 24 h. (B and C) FACS analysis
of intra-cellular staining of VEGF in (B) ECs (Lin- CD45- CD31+) and (C) HSCs (Lin- ckithi CD150+CD48- CD34-) from wild-type (WT) mice treated as described in (A).
Data are presented as fold change in mean fluorescence intensity (MFI). (D) FACS analysis of VEGFR2 expression on ECs (Lin- CD45- CD31+) from WT mice treated
as described in (A). (E) FACS analysis of percentage of BrdU positive HSCs (Lin- ckithi CD150+ CD48-) from WT mice treated as described in (A) and BrdU (18 mg/kg,
16 h). (F) Representative bone marrow section (Laminin in green, DAPI in blue) from WT mice treated as described in (A). (G) FACS analysis of the expression of
Laminin, VE-Cadherin and ESAM on ECs (Lin- CD45- CD31+) from WT mice treated as described in (A).  Data are representative of 3 or more (A-D, E-G) and 2 or more
(E) independent experiments and are presented as mean±Standard Error of Mean (SEM) (n≥3). Statistical analysis was performed using unpaired Student t-test (two-
tailed). ns (not significant), *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Figure 8. Acute IFNα-stimulation of BM ECs is mediated
by VEGF signaling in both hematopoietic and non-
hematopoietic cells. Model depicting BM vasculature
remodeling following stimulation of BM hematopoietic or
non-hematopoietic cells by acute interferon α (IFNα)
treatment.   
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tem. Our data suggest a role for VEGF signaling in the BM
in IFNα-mediated BM EC activation. This rapid, transient
effect may be an emergency response to inflammatory sig-
naling, coming from the hematopoietic system and affect-
ing BM EC niche cells. This response may in turn facilitate
the maintenance of BM homeostasis. In this acute setting,
the vasculature may be rapidly 'primed' or activated, likely
in anticipation of greater insult. In contrast to treatment
with an isolated cytokine, initial inflammatory signaling
during a full infection is followed by production of other
cytokines, and stimulation of additional signaling.32 It is,
therefore, likely that the response elicited by an isolated
cytokine differs to that elicited by a full infection, particu-
larly with regard to continuation of signaling and recovery
from the initial stimulation.
We have found that acute pI:C exposure results in a tran-
sient expansion of the vasculature in the BM after 24 h. The
integrity of this expanded vasculature was compromised
(Figure 1). Increased BM vascular permeability is in keeping
with an increase in the transit of immune cells or leakage of
plasma during an inflammatory response.33   Acute pI:C
treatment induces production of IFNα and mimics an acute
inflammatory response.16 Acute IFNα treatment in vitromay
reduce apoptosis of endothelial cell lines.27 Whether IFNα
has a similar effect on apoptosis of ECs in vivo is unknown.
Reduced BM EC apoptosis, mediated by IFNα during
inflammatory stress, may influence vessel integrity.
Permeability of different types of BM vasculature is
distinct.7 Therefore, the integrity of specific BM vessels fol-
lowing an acute inflammatory response is likely influenced
by vessel permeability under homeostasis. This may be a
mechanism to maintain BM homeostasis during the early
stages of an inflammatory response.
The effects of IFNα on ECs and other hematopoietic cell
types in vivo are in contrast to the in vitro situation26,28,34-36
where cells are isolated from their niche environment. In
the BM niche, IFNα treatment rapidly and efficiently stim-
ulates HSC proliferation in vivo, whereas in vitro, HSCs do
not undergo increased proliferation.16 We have shown BM
EC activation in response to acute IFNα exposure in vivo
(Figures 2 and 3), in contrast to the described effect of IFNα
on ECs in vitro. In addition to the differential effect of IFNα
in vitro and in vivo, IFNα has also been described as being
both stimulatory and inhibitory with regard to VEGF signal-
ing.37-39 We find that VEGF production was increased in the
BM in response to pI:C (Figure 6). BM EC activation follow-
ing acute pI:C treatment was dependent in part on VEGF
signaling (Figure 7). pI:C mediated HSC proliferation was
not affected by inhibition of VEGF, using Avastin treatment
(Figure 7E). This corresponds with previous data showing
that HSCs are directly activated by IFNα.16 An IFNα-medi-
ated increase of VEGF is in contrast to previous studies,
which suggest that VEGF is suppressed by long-term IFN
treatment or in combination  with chemotherapy.38-41
Together, these data highlight the contrast between chronic
versus acute IFN treatments, and between in vitro and in vivo
cytokine responses. As inflammatory stress is a complex
signaling cascade, the in vivo cytokine response in mice is,
therefore, more reflective of the inflammatory response
than the in vitro situation.
In the BM niche, signaling between different cell types is
imperative for maintenance of cellular homeostasis and a
rapid response to inflammation. ECs and the vasculature
itself have been ascribed many functions in the BM as regu-
lators of HSCs.8,10,13,18,42-45 Furthermore, there are distinct vessel
subtypes within the BM which differentially regulate
hematopoiesis.7 In addition, Notch signaling in BM ECs has
been shown to expand the HSC niche in vivo.8 As Notch sig-
naling is involved in the inflammatory response of ECs,46
these data may further support a role for inflammatory sig-
naling in BM niche remodeling. Furthermore, IFNα does not
lead to mobilization of hematopoietic stem progenitor cells
HSPCs that are not in the BM.16,35   However, the percentage
of HSCs found within 20 mm of arterioles in sternal BM is sig-
nificantly reduced following treatment with pI:C in compar-
ison to the control.18 These data suggest that the location of
HSCs in the BM is affected by pI:C. Relocating HSPCs can
potentially affect many different BM cell types, and the BM
vasculature, following treatment with pI:C. Whether pI:C-
stimulated BM vasculature affects the location of HSPCs
within the BM remains unclear. Many cytokines produced
by hematopoietic cells, such as EPO and GCSF, have been
shown to affect specific EC functions in isolation.47,48
However, signaling from the hematopoietic system to the
ECs in the BM niche has not been examined in detail. To
address this question, we have created BM chimeras in
which only either hematopoietic cells or niche cells respond
directly to IFNα. Using this system, we have demonstrated
that inflammatory signaling from an activated hematopoietic
system can affect the BM vasculature (Figure 4). Platelets,
which can induce EC stimulation,30 do not play a major role
in BM EC stimulation in this setting (Figure 5). As the inflam-
matory response is complex, these data do not exclude the
possibility that IFNα-mediated signaling from other cell types
within the BM, in addition to hematopoietic cells, may be
involved in this response. Further, these data cannot discrim-
inate within the heterogeneous population of BM ECs.
Whether there is crosstalk between pI:C-stimulated BM ECs
and BM HSPCs within this context, remains to be elucidated.
Importantly, we demonstrate that BM hematopoietic cells,
including HSCs, are implicated in the pI:C-mediated BM EC
stimulation, and thus in vasculature remodeling. This pro-
vides evidence for crosstalk between BM HSPCs and ECs
under inflammatory stress conditions (Figure 8).
Our findings demonstrate a novel response of the BM
vasculature to primary inflammatory signaling. We have
revealed potential crosstalk between the hematopoietic sys-
tem and the BM vasculature under inflammatory stress.
The transient activation of the BM vasculature represents a
novel, emergency response of the BM stem cell niche to
inflammation. Future studies will likely uncover other
emergency situations in which HSCs influence the BM
niche. Understanding this critical cellular relationship under
stress conditions such as infection, but also chemotherapy,
may reveal new mechanisms for the maintenance and
recovery of BM homeostasis. 
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